Company Overview
The Oncology Institute, Inc. operates as a healthcare entity dedicated to providing a comprehensive array of oncology services throughout the United States. The company executes its operations through three distinct segments: specialty pharmacy, patient services, and clinical trials along with other related activities. This entity functions within the broader healthcare sector, specifically categorized under the medical care facilities industry, which implies a focus on delivering direct patient care and specialized treatment environments. In terms of scale, the company holds a market capitalization of $308.38M and reported annual revenue of $502.73M based on trailing twelve-month data. Additionally, the organization employs 641 individuals to support its service delivery model. These financial figures indicate that the company maintains a mid-cap valuation while generating substantial top-line revenue, positioning it as a significant player within the specialized medical care landscape despite its current profitability challenges.
Financial Health
The company reported revenue of $502.73M for the trailing twelve months, yet this generated a net income of -$50,305,000 and an EBITDA of -$29,139,000. The substantial gap between the positive revenue of $502.73M and the negative net income reveals a cost structure where operating expenses and losses significantly outweigh earnings before interest and taxes. The entity recorded a free cash flow of -$11,004,375, which indicates a cash-burning operation that limits financial flexibility and suggests a need for external capital or future profitability to sustain operations. Margins across the business are negative or compressed, with a gross margin of 15.2%, an operating margin of -4.9%, and a profit margin of -12.1%. The gross margin of 15.2% suggests that the company retains a moderate portion of revenue after direct costs, while the negative operating margin of -4.9% and negative profit margin of -12.1% indicate that overhead costs and general expenses are eroding profitability at a significant rate. Regarding liquidity, the company holds $33.56M in cash against total debt of $103.75M, creating a net debt position, and the debt-to-equity ratio is listed as N/A due to the capital structure. The current ratio stands at 1.59, which indicates that the company has sufficient current assets to cover its short-term liabilities, providing a baseline level of short-term liquidity despite the long-term debt burden. Return on Equity is N/A and return on assets is -13.4%, which reveals that management effectiveness in generating returns is currently negative, as the company is consuming assets rather than generating profit from them.
Valuation Assessment
The trailing P/E ratio is N/A because the company is currently unprofitable, while the forward P/E stands at -19.50. The difference between these metrics implies that the market is pricing in an expectation of future earnings recovery, though a negative forward multiple suggests that projected earnings remain below zero for the near term. The price-to-book ratio is -19.62, which indicates that the market is valuing the company at a negative multiple of its book value, reflecting the asset-light nature of the business or significant liabilities outweighing assets. Alternative valuation metrics include a price-to-sales ratio of 0.61 and an EV/EBITDA of -12.99. These figures suggest that the market is valuing the company primarily on its revenue generation capabilities rather than earnings power, as the negative EV/EBITDA highlights ongoing operational losses relative to enterprise value. The stock has traded between a 52-week high of $4.88 and a 52-week low of $0.97. Without the current share price explicitly provided in the facts, the valuation context is defined by this wide range, suggesting high volatility or a speculative trading environment where the stock price can fluctuate significantly relative to the low and high points. The beta value is 0.21, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting the stock moves with less intensity than the overall market index.
Growth & Income
The company demonstrated a revenue growth rate of 41.6% year-over-year, while the earnings growth rate is N/A due to the negative earnings history. Since earnings are negative, there is no earnings growth to compare directly to revenue growth, but the strong revenue expansion implies that top-line business is scaling rapidly despite the current lack of profitability. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This non-dividend status implies that the company retains all its earnings—or rather, its remaining capital—to reinvest into growth initiatives rather than distributing cash to shareholders. The overall growth and income profile is characterized by rapid top-line expansion of 41.6% coupled with a complete lack of current income distribution, reflecting a strategy focused on market penetration and service scaling in the oncology sector.